Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, April 2006, p. 1143-1147, Vol. 50, No. 4
0066-4804/06/$08.00+0 doi:10.1128/AAC.50.4.1143-1147.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
and
Tomoko Yamamoto1*
Department of Microbiology and Molecular Genetics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, 263-8522,1 Microbiology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tokyo, 174-8511, Japan2
Received 24 March 2005/ Returned for modification 15 May 2005/ Accepted 5 January 2006
|
|
|---|
|
|
|---|
Several large transposons conferring resistance to more than one antibiotic have been identified. Among these, Tn21, Tn1691, Tn2603, and Tn2424, which are classified as class II transposons, seem to be evolutionarily related (11, 13, 18). On the basis of restriction maps and heteroduplex analyses, we originally proposed that the Tn21-related transposons had descended from an ancestral mercury resistance transposon, resembling Tn2613, by subsequent insertions of antibiotic resistance genes and/or insertion sequences (18). This hypothesis has been supported by sequence data from a large group of these transposons (11). Current knowledge on Tn2610 suggests that it may also have evolved from an ancestral mercury resistance transposon via a series of recombination events resulting in a complex configuration.
To confirm this hypothesis, we determined the complete sequence of Tn2610 and compared its structure to that of other known elements.
|
|
|---|
(supE44
lacU169 [
80 lacZ
M15] hsdR17 recA1 endA1 gyrA96 thi-1 relA1), AB2463 (recA thr leu thi lac gal ara xyl mtl pro his arg str tsx sup), and P3478Rif, a rifampin-resistant mutant of P3478 (thy polA). The Tn2610-containing plasmid used in this study was pTKY170, formerly termed pMK1::Tn2610#4 (20). Subcloning for DNA sequencing was performed in pUC18 (17). Plasmids pTKY171 and pTKY172 are pAO3 derivatives carrying Tn1722 and Tn1722 with a kanamycin-resistant determinant, respectively. Plasmid pAO3 is a small derivative of plasmid ColE1 (21). Plasmid pTKY173 is a pTKY172 derivative defective in the tnpA gene. Plasmids pTKY174 and pTKY175 are pACYC184-based plasmids loaded with tnpA genes from Tn2610 and Tn1722, respectively. Bacterial cells were routinely cultured at 37°C in Luria-Bertani (LB) medium or on LB agar. For selection with trimethoprim, Mueller-Hinton agar (Difco Laboratories) was used with 0.5% (vol/vol) lysed horse blood. Antibiotics were added at the following concentrations: ampicillin, 50 µg ml1; chloramphenicol, 25 µg ml1; kanamycin, 50 µg ml1; tetracycline, 25 µg ml1; trimethoprim, 50 µg ml1; rifampin, 100 µg ml1. Construction of plasmids. Plasmid pTKY171 (pAO3::Tn1722) was derived from plasmid pAO3::Tn1721 by deletion of the DNA fragment between the SalI site at nucleotide (nt) 6946 in Tn1721 (Fig. 1) and the BstEII site in pAO3. The pUC4K-derived kanamycin resistance determinant was inserted into the AvaI site at nt 991 in Tn1722 (Fig. 1), resulting in pTKY172. Plasmid pTKY173 is an AvaI-generated deletion of pTKY172 which was cleaved at nt 2855 and nt 4562 in Tn1722 and self-ligated. The DNA fragment between the EcoRI site at nt 13 and the BamHI site at nt 4157 in Tn2610 from pTKY170 was cloned into BamHI-digested pACYC184, resulting in pTKY174. Plasmid pTKY175 was constructed by cloning of the DNA fragment between nt 13 and nt 5624 in Tn1722 into EcoRI-digested pACYC184.
![]() View larger version (11K): [in a new window] |
FIG. 1. Structure of the transposition modules forming the backbone of Tn2610. Arrows above open bars indicate the transcription orientations of the ORFs. Restriction cleavage sites shown are those used for the construction of plasmid derivatives described in Materials and Methods. The structures and restriction sites are based on GenBank sequences for Tn2610 (accession no. AB207867) and Tn1721 (X61367). Abbreviations: A, AvaI; B, BamHI; E, EcoRI; S, SalI.
|
DNA isolation and restriction mapping. Plasmid DNA for restriction analysis and cloning was isolated by the alkaline lysis method (3). Restriction enzymes (TaKaRa Bio Inc., TOYOBO) were used in accordance with the manufacturer's instructions. DNA fragments were separated by electrophoresis on 1% (wt/vol) agarose gels, and individual fragments were isolated from the gels using a QIAEX II gel extraction kit (QIAGEN). HindIII-digested lambda phage DNA fragments and HinfII-digested pBR322 plasmid DNA fragments were used as size markers.
Sequence analysis. Sequencing was performed in the facility at QIAGEN, Japan, on an ABI PRISM model 3100 sequencer. DNA sequences were assembled using the GENETYX version 10.1 software package. PCR was used to amplify the pTKY170 fragments to confirm the boundaries between the cloned fragments predicted by mapping and to obtain sequences. The sequence obtained was used to query the GenBank database in order to identify putative genes by using the BLAST program via the World Wide Web interface of the National Center for Biotechnology Information (http://www.ncbi.nlm.nih/BLAST).
Nucleotide sequence accession number. The 23,883-bp sequence of Tn2610 has been submitted to the DDBJ/EMBL/GenBank databases under accession no. AB207867.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Features of ORFs and discrete DNA segments in Tn2610
|
![]() View larger version (37K): [in a new window] |
FIG. 2. Genetic organization of Tn2610 based on complete nucleotide sequence analysis. Labeled lines represent the regions in which sequences exhibit significant homology to extant sequences on various genetic elements. The accession numbers of the sequences used for comparative analysis are given in Table 1.
|
![]() View larger version (19K): [in a new window] |
FIG. 3. Comparison of the 38-bp inverted repeats (A) and res sites (B). The sequences of the 38-bp inverted repeats and res sites in Tn2610 IRa (this study), Tn1721 (accession no. X61367), and Tn21 (accession no. AF071413) are aligned, with asterisks indicating identical bases. The res subsites (9) are boxed, and the AT site at which resolvase-mediated recombination takes place is boldfaced. The recombination crossover point to generate the hybrid res is indicated by a vertical arrow. tnpR and tnpM, regions adjacent to each end of the res sites.
|
Our earlier analysis indicated that tnpA in IRb is functional, while tnpA in IRa is not functional, in the transposition of Tn2610 (19). Although the IRa module shows strong homology to that of Tn1721, the corresponding genes are not identical. The tnpA gene in IRa differs from the Tn1721 sequence at nine positions, leading to the alteration of 7 amino acid residues. Furthermore, a 3-base difference is found in the 38-bp IR sequences between IRa and Tn1721 (Fig. 3A). Therefore, the inability of tnpA in IRa to promote the transposition of Tn2610 may be due to a mutation. To determine whether the tnpA gene of IRa is active, the ability of the product to promote the transposition of Tn1721 was examined by complementation analysis of a Tn1722 tnpA-defective mutant as described in Materials and Methods. As shown in Table 2, the tnpA gene in IRa complemented the tnpA defect in Tn1722, suggesting that it is active even though it cannot promote the transposition of Tn2610. The Tn1721-like tnpA product of IRa probably cannot recognize the 38-bp element at the end of IRb, while the Tn21-like tnpA product of IRb recognizes both 38-bp elements, even though they are imperfect. This hypothesis is supported by a report showing that the Tn21 tnpA products can act on the IR of Tn501 (which is identical to the IR of Tn1721) but the Tn501 tnpA product cannot promote the transposition of Tn21 (8).
|
View this table: [in a new window] |
TABLE 2. Complementation of a Tn1722 tnpA mutant
|
The Tn1721-like transposition module merges (at the res site) with a Tn21-derived sequence (nt 3565 to 5376) including tnpM and the 5' conserved segment (5'-CS) of the class 1 integron (the insertion site of the integron IRi into tnpM is identical to that in Tn21). The intI1 gene, in this case, is not preceded by an attI1 site (14) with inserted gene cassettes but by a segment containing the ereB gene (2) with part of CR3 (15). The right-hand boundary of CR3 merges with a long region (nt 7339 to 14134) identical to a part of Salmonella genomic island I (SGI1) (5) of Salmonella enterica serovar Typhimurium phage type DT104 except for the presence of an additional aadA2 cassette in Tn2610. This region includes orf2 (5, 11), the remnant of the 5'-CS of a class 1 integron containing an intI1-groEL hybrid, two gene cassettes (blaPSE-1 and aadA2), and the 3'-CS of a class 1 integron including qacE
1, sul1, orf5, and orf6
(Fig. 2), which is also identical to that found in In2 carried on Tn21 (11, 15). The homology with In2 continues down to the tniA gene, which is interrupted by the IS26 insertion element (at nt 20333) located between this region and IRb (Fig. 2).
This complex mosaic structure is likely derived by multiple recombination events which involved Tn21-like and SGI1-like sequences, as well as other sequences.
Concluding remarks. The present study has shown that Tn2610 is a composite transposon comprising two transposition modules, Tn1721-like IRa and Tn21-derived IRb, surrounding a central region containing the drug resistance genes ereB, pse-1, aadA2, and sul1. It is proposed that the ancestors of Tn1721 and Tn21 were independently inserted into a plasmid or genome via transposition events catalyzed by their own transposition modules, leading to the backbone of Tn2610. Later, genes could have been lost by deletion during or after the acquisition of the regions that include the integrons. This seems plausible, since a transposon carrying mphB with an organization very similar to that of the transposition modules in Tn2610 has been found in E. coli (12).
SGI1 has been identified in DT104, whose prevalence increased dramatically in the 1990s (4, 5, 7, 10). DT104 isolates have been reported to be resistant to a core group of antibiotics including ampicillin, chloramphenicol, streptomycin, sulfonamide, and tetracycline (commonly abbreviated ACSSuT). Furthermore, a number of variants of SGI1 that are associated with different resistance phenotypes (e.g., ACSSuS plus trimethoprim, SSu, ASu, and ASSuT) have been identified, suggesting that the multidrug resistance region of SGI1 was subject to recombination events that generated variants (4, 6). Since Tn2610 was found in a plasmid from a strain isolated before SGI1-containing strains, it could also have been involved in the generation of SGI1 structures.
This work was supported in part by a grant from the Research Project for Emerging and Reemerging Infectious Diseases (H15-Shinkou-9) from the Ministry of Health, Labor and Welfare of Japan.
Present address: Astellas Pharma Inc., Tukuba, 300-2698, Japan. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»